The Kansas City Clinical Oncology Program (KCCOP) , established and funded by the National Cancer Institute in 1983, and continued in 1987,1990, and 1995, is a community-wide cooperative program of 11 community hospitals and the majority of Kansas City's oncologists. The KCCOP is a 501 (c)(3) not4or-profit whose mission is to support and coordinate community participation in NCI sponsored cancer clinical trials. The KCCOP projects an annual accrual of 95 credits on treatment protocols and 116 on cancer control protocols using the five research bases: Southwest Oncology Group, M.D. Anderson Cancer Center, National Surgical Adjuvant Breast and Bowel Project, Radiation Therapy Oncology Group, and Gynecologic Oncology Group. The KCCOP has a positive record of accrual to clinical trials with the numbers of patients and credits well in excess of the minimum required by the NCI. Over the past four years, KCCOP investigators have accrued 370.1 credits to therapeutic studies and 291.4 cancer control credits for a total of 661.5 credits. The KCCOP has access to a large population base which will ensure continued high accrual to treatment and cancer control trials. The KCCOP has strong support from its 11 member hospitals which further enhances its ability to reach underserved and minority groups within the catchment area. The dedication and the presence of an experienced staff, combined with the expertise and leadership provided by the Principal and Associate Principal Investigators and a group of dedicated physicians, ensure that the KCCOP has the necessary expertise and commitment to continue its involvement in cooperative group activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035176-18
Application #
6375676
Study Section
Special Emphasis Panel (ZCA1-SRRB-7 (J1))
Project Start
1983-09-15
Project End
2005-05-31
Budget Start
2001-06-15
Budget End
2002-05-31
Support Year
18
Fiscal Year
2001
Total Cost
$547,186
Indirect Cost
Name
Kansas City Clinical Oncology Program
Department
Type
DUNS #
148680262
City
Kansas City
State
MO
Country
United States
Zip Code
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8

Showing the most recent 10 out of 147 publications